Profile: Johnson & Johnson (JNJ.N)
Johnson & Johnson, incorporated on November 10, 1887, is engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The business of Johnson & Johnson is conducted by more than 275 operating companies across the world. The Company’s primary focus has been on products related to human health and well-being. The Company's subsidiaries operate 144 manufacturing facilities occupying approximately 21.7 million square feet of floor space. Johnson & Johnson operates three business segments: Consumer, which offers a range of consumer products to general public; Pharmaceutical, which offers health related products through retailers, wholesalers and health care professionals for prescription use, and Medical Devices and Diagnostics, which offers a range of products to physicians, nurses, hospitals, and clinics.
The Consumer segment includes a broad range of products used in the baby care, skin care, oral care, wound care and women’s health care fields, as well as nutritional and over-the-counter pharmaceutical products, and wellness and prevention platforms. The Baby Care franchise includes the JOHNSON’S Baby line of products. The brands in the Skin Care franchise include the AVEENO; CLEAN & CLEAR; DABAO; JOHNSON’S Adult; LUBRIDERM; NEUTROGENA; RoC; and VENDOME product lines. Brands in the Oral Care franchise include the LISTERINE oral care lines. The Wound Care franchise includes BAND-AID brand adhesive bandages and NEOSPORIN first aid products. Brands in the Women’s Health franchise outside of North America are STAYFREE and CAREFREE sanitary pad and o.b. tampon brands. The principal nutritional line is SPLENDA, No Calorie Sweetener. Over-the-counter medicines include the broad family of TYLENOL acetaminophen products; SUDAFED cold, flu and allergy products; ZYRTEC allergy products; MOTRIN IB ibuprofen products; and PEPCID line of heartburn products. These products are marketed to the general public and sold both to retail outlets and distributors across the world.
The Pharmaceutical segment includes products in areas, such as anti-infective, antipsychotic, cardiovascular, contraceptive, gastrointestinal, hematology, immunology, infectious diseases, metabolic, neurology, oncology, pain management, thrombosis and vaccines. These products are distributed directly to retailers, wholesalers and health care professionals for prescription use. Key products in the Pharmaceutical segment include: REMICADE (infliximab), a treatment for a number of immune-mediated inflammatory diseases; SIMPONI (golimumab), a treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; STELARA (ustekinumab), a treatment for adults with moderate to severe plaque psoriasis and active psoriatic arthritis; INCIVO (telaprevir), for the treatment of hepatitis C; INTELENCE (etravirine) and PREZISTA (darunavir), treatments for HIV/AIDS; CONCERTA (methylphenidate HCl) extended-release tablets CII, a treatment for attention deficit hyperactivity disorder; INVEGA (paliperidone) extended-release tablets, for the treatment of schizophrenia and schizoaffective disorder; INVEGA SUSTENNA /XEPLION (paliperidone palmitate), for the treatment of schizophrenia in adults; RISPERDAL CONSTA (risperidone), for the treatment of schizophrenia and for the maintenance treatment of Bipolar I Disorder; VELCADE (bortezomib), a treatment for multiple myeloma; ZYTIGA (abiraterone acetate), a treatment for metastatic castration-resistant prostate cancer; ACIPHEX /PARIET, a proton pump inhibitor co-marketed with Eisai Inc.; PROCRIT (epoetin alfa, sold outside the United States as EPREX), to stimulate red blood cell production; and XARELTO (rivaroxaban), an oral anticoagulant for the prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery, to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, for the treatment of DVT and PE, and for the reduction in the risk of recurrence of DVT and PE.
Medical Devices and Diagnostics
The Medical Devices and Diagnostics segment includes a broad range of products used in the professional fields by physicians, nurses, hospitals, and clinics. These include products to treat cardiovascular disease; orthopaedic and neurological products; blood glucose monitoring and insulin delivery products; general surgery, biosurgical, and energy products; professional diagnostic products; infection prevention products; and disposable contact lenses. These products are distributed to wholesalers, hospitals and retailers both directly and through surgical supply and other distributors.
Johnson & Johnson
1 Johnson And Johnson Plz
NEW BRUNSWICK NJ 08933-0001
Company Web Links
- Pharmacyclics cancer drug successful as combination therapy: independent panel
- UPDATE 1-Pharmacyclics cancer drug successful as combination therapy - independent panel
- CORRECTED-Independent panel recommends unblinding study after Imbruvica shows clear benefit
- Johnson & Johnson sues Glaxo over allergy ads as spring nears
- Tylenol maker to pay $25 million for selling metal-contaminated drugs